Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study.
Egami S, Kawazoe H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Fukunaga K, Yamaguchi M, Nakamura T. Egami S, et al. Among authors: ikemura s. J Cancer. 2021 Feb 16;12(7):2105-2112. doi: 10.7150/jca.53242. eCollection 2021. J Cancer. 2021. PMID: 33754009 Free PMC article.
Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer.
Yoda S, Soejima K, Hamamoto J, Yasuda H, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Naoki K, Betsuyaku T. Yoda S, et al. Among authors: ikemura s. Lung Cancer. 2014 Sep;85(3):366-72. doi: 10.1016/j.lungcan.2014.06.009. Epub 2014 Jun 21. Lung Cancer. 2014. PMID: 25001509
Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.
Hamamoto J, Soejima K, Naoki K, Yasuda H, Hayashi Y, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Arai D, Ishioka K, Ohgino K, Betsuyaku T. Hamamoto J, et al. Among authors: ikemura s. Cancer Sci. 2015 Jan;106(1):34-42. doi: 10.1111/cas.12569. Epub 2014 Dec 8. Cancer Sci. 2015. PMID: 25414083 Free PMC article.
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.
Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, Goto K, Betsuyaku T, Soejima K. Nukaga S, et al. Among authors: ikemura s. Cancer Res. 2017 Apr 15;77(8):2078-2089. doi: 10.1158/0008-5472.CAN-16-2359. Epub 2017 Feb 15. Cancer Res. 2017. PMID: 28202511
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.
Tani T, Naoki K, Yasuda H, Arai D, Ishioka K, Ohgino K, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Soejima K. Tani T, et al. Among authors: ikemura s. Cancer Chemother Pharmacol. 2019 Nov;84(5):1065-1071. doi: 10.1007/s00280-019-03934-y. Epub 2019 Sep 6. Cancer Chemother Pharmacol. 2019. PMID: 31493177 Clinical Trial.
IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.
Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, Kobayashi K, Masuzawa K, Ikemura S, Kawada I, Hayashi Y, Fukui K, Horimoto K, Fukunaga K, Soejima K. Manabe T, et al. Among authors: ikemura s. Mol Cancer Res. 2020 Apr;18(4):549-559. doi: 10.1158/1541-7786.MCR-19-0956. Epub 2020 Jan 15. Mol Cancer Res. 2020. PMID: 31941753
196 results